Ulisse BioMed has developed a technology platform for the selection and production of antiviral DNA aptamers, capable of reducing the infectivity of pathogens and that can be used both for therapeutic and diagnostic purposes. Aptamers are nucleic acid-based molecules that can be selected against any kind of target.
They bind their target with affinity similar or higher than antibodies. Aptamers surely possess several advantages over antibodies, such as to be small, synthetic, robust and easily penetrate tissues. Since aptamers production is obtained by an in vitro chemical reaction, it is process completely cell-free and animal-component-free; this feature can overcome ethical and economic issues of antibodies obtained from animals at a high cost.
Aptamers are synthetic DNA/RNA oligonucleotides that bind with high affinity and specificity to target antigens such as small molecules, peptides, proteins, cells, and tissues.
Aptamer products can be used as research agents, diagnostics, biosensors, and tools for biomarker or drug discovery. Aptamers can also be used for bioindustrial applications and targeted therapeutics. They represent an effective and economical alternative to monoclonal antibodies.
Aptamer products can be used as research agents, diagnostics, biosensors, and tools for biomarker or drug discovery. Aptamers can also be used for bioindustrial applications and targeted therapeutics.
Ulisse BioMed has already developed aptamers for the treatment and prevention of cutaneous HPVs and is actively developing aptamers against sexually transmitted HPVs. Ulisse BioMed plans also to develop aptamers to prevent and treat respiratory pathogen infection, which could be integrated in a nasal spray.
Aptamers could be additives for pharmaceutical or cosmetic products to enhance their therapeutic capabilities. For instance, they could be used in skin creams, oils, condom lubricants and genital gels in order to enhance their features for prevention or treatment of diseases.